CLINICAL_TRIALS ClinicalTrials.gov record update

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. A Phase II Trial.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07574047
Title field or adapter rule: {'original_value': 'MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. A Phase II Trial.', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:29.739748+00:00
Published At: 2026-10-27T00:00:00+00:00
Record Updated At: 2026-10-27
Source Retrieved At: 2026-10-31T22:18:13.198083+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Melanoma", "Advanced Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-27", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07574047"
protocolSection.identificationModule.officialTitle: "MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. A Phase II Trial."
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['ICI Infusions 8-12 h'], 'description': "Morning administration of ICI per physician's choice, according to local practice:\n\nNivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W)\n\nPembrolizumab (Keytruda®) Monotherapy\n\n\\- 200 mg administered intravenously every 3 weeks (Q3W)\n\nIpilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy\n\n* Induction Phase:\n\n * Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W)\n * Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W)\n * Administered for 4 cycles\n* Maintenance Phase:\n\n * Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)", 'name': 'Immune Checkpoint Inhibitors', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['ICI Infusions 15-18 h'], 'description': "Afternooon administration of ICI per physician's choice, according to local practice:\n\nNivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W)\n\nPembrolizumab (Keytruda®) Monotherapy\n\n\\- 200 mg administered intravenously every 3 weeks (Q3W)\n\nIpilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy\n\n* Induction Phase:\n\n * Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W)\n * Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W)\n * Administered for 4 cycles\n* Maintenance Phase:\n\n * Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)", 'name': 'Immune Checkpoint Inhibitors', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.